Secondary malignant neoplasm of other specified sites
ICD-10 C79.89 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of other specified sites.
C79.89 is used to classify secondary malignant neoplasms that occur in sites not specifically identified in other codes. This code is particularly relevant for metastatic disease, where cancer has spread from its original (primary) site to other parts of the body. In many cases, the primary site may be unknown, complicating diagnosis and treatment. The metastatic tumors can arise from various cancers, including breast, lung, prostate, and colorectal cancers, among others. The clinical presentation may vary widely depending on the sites involved, and symptoms can include pain, organ dysfunction, and systemic effects such as weight loss and fatigue. Staging of metastatic disease is crucial for treatment planning and prognosis, often utilizing the TNM (Tumor, Node, Metastasis) system. Palliative care considerations are also essential, as many patients with secondary malignancies may require symptom management and supportive care to improve quality of life, especially in advanced stages of disease.
Detailed documentation of the primary cancer diagnosis, staging, and treatment plans.
Patients with known primary cancers presenting with new metastatic lesions.
Accurate documentation of the metastatic sites and any changes in treatment regimens.
Comprehensive symptom management plans and patient goals of care.
Patients with advanced metastatic disease requiring symptom relief.
Focus on quality of life and patient-centered care approaches.
Used for follow-up visits for patients with metastatic disease.
Documentation of the patient's history, examination, and medical decision-making.
Oncology practices may require additional documentation related to treatment plans.
C79.89 should be used when documenting secondary malignant neoplasms that do not fall under more specific codes, particularly when the metastatic site is known but not specified in other codes.